Borrowable Liquidity Scarce In Vascular Biogenics
Interactive Brokers - Seeking Alpha - Mon Mar 30, 3:33PM CDT
Prior to January of this year, Vascular Biogenics Ltd. (NASDAQ: VBLT ) was a thinly traded stock with only a few thousand shares trading per day, on average. In January, the price per share increased substantially, rallying 180% from $6.00 at the...
VBLT: 4.23 (+0.07)
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 27, 5:10PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
LOXO: 13.60 (+0.21), IMDZ: 26.56 (-0.42), TRVN: 6.69 (-0.30), AMSC: 6.88 (-3.12), ORMP: 7.45 (+0.08), SCYX: 9.47 (-0.52), GPIC: 12.00 (-0.70), SCMP: 21.09 (-0.31), WRLD: 74.78 (-0.56), VBLT: 4.23 (+0.07), CBMG: 29.51 (-1.85)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 11:49AM CDT
TRVN: 6.69 (-0.30), WGO: 21.06 (+0.29), CCSC: 5.42 (-0.15), OTIV: 1.50 (-0.10), DPLO: 36.71 (+0.46), CNAT: 6.66 (-0.15), WGBS: 4.62 (+0.05), HKTV: 9.11 (+1.44), DVD: 2.39 (-0.02), SEDG: 24.89 (+0.10), ENVA: 19.33 (-0.33), SEED: 1.77 (+0.16), RHT: 76.83 (-0.02), SCMP: 21.09 (-0.31), SGNT: 25.20 (-0.40), WRLD: 74.78 (-0.56), VBLT: 4.23 (+0.07), RCON: 1.90 (-0.10), SNDK: 67.92 (-0.84)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 8:13AM CDT
EXXI: 4.16 (+0.06), OTIV: 1.50 (-0.10), CNAT: 6.66 (-0.15), EXAS: 21.98 (-1.08), WGBS: 4.62 (+0.05), FIVE: 36.04 (+0.10), ROSG: 3.72 (+0.06), NVAX: 8.58 (-0.07), RHT: 76.83 (-0.02), SCMP: 21.09 (-0.31), CLLS: 32.61 (-0.07), MAGS: 4.90 (unch), VBLT: 4.23 (+0.07), SNDK: 67.92 (-0.84)
Nasdaq stocks posting largest volume increases
AP - Wed Mar 25, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
WBB: 17.20 (-0.11), OTIV: 1.50 (-0.10), TRGT: 2.43 (+0.04), SEED: 1.77 (+0.16), ORMP: 7.45 (+0.08), FCAP: 24.35 (-0.53), ASUR: 5.40 (-0.19), LIME: 2.83 (-0.06), KRFT: 87.57 (-0.81), VBLT: 4.23 (+0.07), FNJN: 1.39 (-0.06), DGLY: 13.88 (+0.39), KFX: 11.02 (-0.01)
VBL Therapeutics' lead drug candidate successful in brain cancer study; shares up 18% premarket
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 7:49AM CDT
VBLT: 4.23 (+0.07)
Vascular Biogenics FY14 results
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 6:41AM CDT
VBLT: 4.23 (+0.07)
Vascular Biogenics beats by $0.10
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 6:09AM CDT
VBLT: 4.23 (+0.07)
VBL Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Wed Mar 25, 6:00AM CDT
-Will host conference call at 8:30 am ET today-
VBLT: 4.23 (+0.07)
VBL Therapeutics Reports Interim Topline Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM)
GlobeNewswire - Wed Mar 25, 6:00AM CDT
VBL Therapeutics (Nasdaq:VBLT), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced top-line interim results from its ongoing Phase 2 study of VB-111 in patients with recurrent glioblastoma (rGBM), which demonstrated a statistically significant improvement in overall survival in patients treated with VB-111 followed by VB-111 in combination with bevacizumab (Avastin(R)) upon disease progression, compared to patients treated with VB-111 followed by bevacizumab alone upon disease progression (p=0.05). Study results will be presented in conjunction with the American Society of Cancer Oncology (ASCO) Annual Meeting, May 29th-June 2nd, 2015 in Chicago, Illinois.
VBLT: 4.23 (+0.07)
Vascular Biogenics (VBLT) Jumps: Stock Moves 5.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 24, 7:30AM CDT
Vascular Biogenics Ltd. (VBLT) was a big mover last session, as the company saw its shares rise over 5% on the day.
ACOR: 33.12 (-0.38), VBLT: 4.23 (+0.07)